SCHEMBL6992124

SCHEMBL6992124

O=c1[nH]c2ccc(C(O)=S)cc2o1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
NOS1 P29475 4/20 0.54
SMYD3 Q9H7B4 2/20 0.49
PDE3B Q13370 1/20 0.47
PDE3A Q14432 1/20 0.47
OGT O15294 1/20 0.47
ESR1 P03372 1/20 0.44
KMO O15229 1/20 0.44
PSMB8 P28062 1/20 0.44
POLB P06746 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
NOS3 P29474 3/20 0.42
NOS2 P35228 3/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
ADRA2A P08913 1/20 0.42
TSHR P16473 1/20 0.42
THPO P40225 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29771053 0.84 KDM4E (0.67) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL118684 0.84 KDM4E (0.67) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL13146791 0.83 CREBBP (0.60) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL6992123 0.79 CREBBP (0.65) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL2546849 0.79 CREBBP (0.69) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL349741 0.79 CREBBP (0.65) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL2316982 0.79 KDM4E (0.69) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL6647933 0.79 ALDH1A1 (0.60) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL9684977 0.76 ALDH1A1 (0.57) CREBBPKDM4EALDH1A1NOS1SMYD3
SCHEMBL9683724 0.76 ALDH1A1 (0.69) CREBBPKDM4EALDH1A1NOS1SMYD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642256-B2 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders WARNER-LAMBERT COMPANY LLC 2003-11-04 US disclosed
EP-1345935-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS Warner-Lambert Company LLC (US) 2003-09-24 EP disclosed
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists KORNBERG BRIAN EDWARD (US) 2003-01-23 US disclosed
WO-2002050070-A2 PIPERIDINE DERIVATIVES AS SUBTYPE SELECTIVE N-METHYL-D-ASPARTATE ANTAGONISTS WARNER-LAMBERT COMPANY LLC (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018021-A1 Piperidine derivatives as subtype selective N-methyl-D-aspartate antagonists GRIN1, OPRD1, OPRM1 CREBBP 1115/4885KDM4E 2119/4885ALDH1A1 445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.